SCHEMBL6321462

SCHEMBL6321462

O=C1Cc2c(cccc2-c2ccccc2F)N1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNB2 O95067 13/20 0.48
CDK1 P06493 13/20 0.48
CCNB1 P14635 13/20 0.48
GSK3B P49841 13/20 0.48
CCNB3 Q8WWL7 13/20 0.48
CDK5 Q00535 12/20 0.48
CDK5R1 Q15078 12/20 0.48
CCNT1 O60563 2/20 0.48
CCNA2 P20248 2/20 0.48
CDK2 P24941 2/20 0.48
CDK9 P50750 2/20 0.48
CCNA1 P78396 2/20 0.48
SIRT2 Q8IXJ6 1/20 0.48
SIRT1 Q96EB6 1/20 0.48
JAK2 O60674 1/20 0.46
AHR P35869 1/20 0.46
PDK2 Q15119 1/20 0.46
SRD5A1 P18405 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL156843 0.89 JAK2 (0.45) CCNB2CDK1CCNB1GSK3BCCNB3
SCHEMBL153534 0.87 CCNB2 (0.44) CCNB2CDK1CCNB1GSK3BCCNB3
SCHEMBL6321256 0.84 GSK3B (0.52) CCNB2CDK1CCNB1GSK3BCCNB3
SCHEMBL261277 0.84 AHR (0.48) CCNB2CDK1CCNB1GSK3BCCNB3
SCHEMBL29622013 0.84 AHR (0.48) CCNB2CDK1CCNB1GSK3BCCNB3
SCHEMBL152272 0.82 GSK3B (0.50) CCNB2CDK1CCNB1GSK3BCCNB3
SCHEMBL10710490 0.80 CCNB2 (0.48) CCNB2CDK1CCNB1GSK3BCCNB3
SCHEMBL6323945 0.80 JAK2 (0.49) CCNB2CDK1CCNB1GSK3BCCNB3
SCHEMBL6328115 0.80 CCNB2 (0.58) CCNB2CDK1CCNB1GSK3BCCNB3
SCHEMBL152280 0.80 CCNB2 (0.51) CCNB2CDK1CCNB1GSK3BCCNB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 CCNB2 694/4885CDK1 51/4885CCNB1 449/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 CCNB2 694/4885CDK1 51/4885CCNB1 449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.